Sitagliptin Mitigates Diabetic Cardiomyopathy Through Oxidative Stress Reduction and Suppression of VEGF and FLT-1 Expression in Rats Article Swipe
Qamraa H. Alqahtani
,
Tahani Almatrafi
,
Amira M. Badr
,
Sumayya A. Alturaif
,
Raeesa Mohammed
,
Abdulaziz Siyal
,
Iman H. Hasan
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/biom15081104
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/biom15081104
Diabetes mellitus (DM) is a global health challenge marked by chronic hyperglycemia, which can result in complications such as diabetic cardiomyopathy. Sitagliptin, an oral anti-hyperglycemic drug, has demonstrated efficacy in alleviating cardiovascular complications associated with DM. This study explored the impact of Sitagliptin’s potential as a therapeutic agent, functioning not only to control blood sugar levels but also to enhance vascular health and strengthen cardiac resilience in diabetes. The investigation focused on alterations in the vascular endothelial growth factor (VEGF) and its receptor-1 (FLT-1) signaling pathways, as well as its potential to suppress inflammation and oxidative stress. A number of rats received a single dose of streptozotocin (STZ) 55 mg/kg (i.p.) to induce DM. Sitagliptin was administered orally (100 mg/kg/90 days) to normal and diabetic rats, after which samples were collected for investigation. Sitagliptin significantly mitigated weight loss in diabetic rats. Its administration significantly reduced blood glucose levels and improved serum troponin I and CK-MB levels. Heart sections from diabetic rats showed a marked increase in mTOR, VEGF, and FLT-1 immune reaction, while sitagliptin-treated diabetic rats’ heart sections showed moderate immune reactions. Sitagliptin’s protective effect was also associated with reduced inflammation, and apoptotic markers. In conclusion, Sitagliptin is suggested to offer beneficial effects on the vascular health of cardiac blood vessels, thereby potentially reducing myocardial stress in diabetic patients.
Related Topics
Concepts
Sitagliptin
Oxidative stress
Diabetic cardiomyopathy
VEGF receptors
Internal medicine
Cardiology
Medicine
Cardiomyopathy
Reduction (mathematics)
Diabetes mellitus
Endocrinology
Heart failure
Type 2 diabetes
Geometry
Mathematics
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/biom15081104
- https://www.mdpi.com/2218-273X/15/8/1104/pdf?version=1753861922
- OA Status
- gold
- References
- 63
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4412756066
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4412756066Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/biom15081104Digital Object Identifier
- Title
-
Sitagliptin Mitigates Diabetic Cardiomyopathy Through Oxidative Stress Reduction and Suppression of VEGF and FLT-1 Expression in RatsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-07-30Full publication date if available
- Authors
-
Qamraa H. Alqahtani, Tahani Almatrafi, Amira M. Badr, Sumayya A. Alturaif, Raeesa Mohammed, Abdulaziz Siyal, Iman H. HasanList of authors in order
- Landing page
-
https://doi.org/10.3390/biom15081104Publisher landing page
- PDF URL
-
https://www.mdpi.com/2218-273X/15/8/1104/pdf?version=1753861922Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.mdpi.com/2218-273X/15/8/1104/pdf?version=1753861922Direct OA link when available
- Concepts
-
Sitagliptin, Oxidative stress, Diabetic cardiomyopathy, VEGF receptors, Internal medicine, Cardiology, Medicine, Cardiomyopathy, Reduction (mathematics), Diabetes mellitus, Endocrinology, Heart failure, Type 2 diabetes, Geometry, MathematicsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
63Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4412756066 |
|---|---|
| doi | https://doi.org/10.3390/biom15081104 |
| ids.doi | https://doi.org/10.3390/biom15081104 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40867548 |
| ids.openalex | https://openalex.org/W4412756066 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | Q000494 |
| mesh[1].descriptor_ui | D000068900 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | pharmacology |
| mesh[1].descriptor_name | Sitagliptin Phosphate |
| mesh[2].qualifier_ui | Q000627 |
| mesh[2].descriptor_ui | D000068900 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | therapeutic use |
| mesh[2].descriptor_name | Sitagliptin Phosphate |
| mesh[3].qualifier_ui | Q000187 |
| mesh[3].descriptor_ui | D018384 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | drug effects |
| mesh[3].descriptor_name | Oxidative Stress |
| mesh[4].qualifier_ui | Q000378 |
| mesh[4].descriptor_ui | D040281 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | metabolism |
| mesh[4].descriptor_name | Vascular Endothelial Growth Factor Receptor-1 |
| mesh[5].qualifier_ui | Q000235 |
| mesh[5].descriptor_ui | D040281 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | genetics |
| mesh[5].descriptor_name | Vascular Endothelial Growth Factor Receptor-1 |
| mesh[6].qualifier_ui | Q000188 |
| mesh[6].descriptor_ui | D058065 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | drug therapy |
| mesh[6].descriptor_name | Diabetic Cardiomyopathies |
| mesh[7].qualifier_ui | Q000378 |
| mesh[7].descriptor_ui | D058065 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | metabolism |
| mesh[7].descriptor_name | Diabetic Cardiomyopathies |
| mesh[8].qualifier_ui | Q000473 |
| mesh[8].descriptor_ui | D058065 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | pathology |
| mesh[8].descriptor_name | Diabetic Cardiomyopathies |
| mesh[9].qualifier_ui | Q000378 |
| mesh[9].descriptor_ui | D042461 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | metabolism |
| mesh[9].descriptor_name | Vascular Endothelial Growth Factor A |
| mesh[10].qualifier_ui | Q000235 |
| mesh[10].descriptor_ui | D042461 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | genetics |
| mesh[10].descriptor_name | Vascular Endothelial Growth Factor A |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D051381 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Rats |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D008297 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Male |
| mesh[13].qualifier_ui | Q000188 |
| mesh[13].descriptor_ui | D003921 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | drug therapy |
| mesh[13].descriptor_name | Diabetes Mellitus, Experimental |
| mesh[14].qualifier_ui | Q000378 |
| mesh[14].descriptor_ui | D003921 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | metabolism |
| mesh[14].descriptor_name | Diabetes Mellitus, Experimental |
| mesh[15].qualifier_ui | Q000150 |
| mesh[15].descriptor_ui | D003921 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | complications |
| mesh[15].descriptor_name | Diabetes Mellitus, Experimental |
| mesh[16].qualifier_ui | Q000187 |
| mesh[16].descriptor_ui | D001786 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | drug effects |
| mesh[16].descriptor_name | Blood Glucose |
| mesh[17].qualifier_ui | Q000494 |
| mesh[17].descriptor_ui | D007004 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | pharmacology |
| mesh[17].descriptor_name | Hypoglycemic Agents |
| type | article |
| title | Sitagliptin Mitigates Diabetic Cardiomyopathy Through Oxidative Stress Reduction and Suppression of VEGF and FLT-1 Expression in Rats |
| biblio.issue | 8 |
| biblio.volume | 15 |
| biblio.last_page | 1104 |
| biblio.first_page | 1104 |
| topics[0].id | https://openalex.org/T10401 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9997000098228455 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2712 |
| topics[0].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[0].display_name | Diabetes Treatment and Management |
| topics[1].id | https://openalex.org/T10821 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9990000128746033 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2705 |
| topics[1].subfield.display_name | Cardiology and Cardiovascular Medicine |
| topics[1].display_name | Cardiovascular Function and Risk Factors |
| topics[2].id | https://openalex.org/T11339 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9945999979972839 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Metabolism, Diabetes, and Cancer |
| is_xpac | False |
| apc_list.value | 2100 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2273 |
| apc_paid.value | 2100 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2273 |
| concepts[0].id | https://openalex.org/C2779284873 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9019532203674316 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q419832 |
| concepts[0].display_name | Sitagliptin |
| concepts[1].id | https://openalex.org/C2776151105 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7323113083839417 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q898814 |
| concepts[1].display_name | Oxidative stress |
| concepts[2].id | https://openalex.org/C2776553924 |
| concepts[2].level | 4 |
| concepts[2].score | 0.6859761476516724 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q5270132 |
| concepts[2].display_name | Diabetic cardiomyopathy |
| concepts[3].id | https://openalex.org/C167734588 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6659919023513794 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q4356503 |
| concepts[3].display_name | VEGF receptors |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6258540153503418 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C164705383 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5118405222892761 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q10379 |
| concepts[5].display_name | Cardiology |
| concepts[6].id | https://openalex.org/C71924100 |
| concepts[6].level | 0 |
| concepts[6].score | 0.501868486404419 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[6].display_name | Medicine |
| concepts[7].id | https://openalex.org/C2778797674 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4827372431755066 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q847583 |
| concepts[7].display_name | Cardiomyopathy |
| concepts[8].id | https://openalex.org/C111335779 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4755506217479706 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q3454686 |
| concepts[8].display_name | Reduction (mathematics) |
| concepts[9].id | https://openalex.org/C555293320 |
| concepts[9].level | 2 |
| concepts[9].score | 0.4175075888633728 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[9].display_name | Diabetes mellitus |
| concepts[10].id | https://openalex.org/C134018914 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3672904670238495 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[10].display_name | Endocrinology |
| concepts[11].id | https://openalex.org/C2778198053 |
| concepts[11].level | 2 |
| concepts[11].score | 0.21506723761558533 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q181754 |
| concepts[11].display_name | Heart failure |
| concepts[12].id | https://openalex.org/C2777180221 |
| concepts[12].level | 3 |
| concepts[12].score | 0.11424872279167175 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q3025883 |
| concepts[12].display_name | Type 2 diabetes |
| concepts[13].id | https://openalex.org/C2524010 |
| concepts[13].level | 1 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q8087 |
| concepts[13].display_name | Geometry |
| concepts[14].id | https://openalex.org/C33923547 |
| concepts[14].level | 0 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q395 |
| concepts[14].display_name | Mathematics |
| keywords[0].id | https://openalex.org/keywords/sitagliptin |
| keywords[0].score | 0.9019532203674316 |
| keywords[0].display_name | Sitagliptin |
| keywords[1].id | https://openalex.org/keywords/oxidative-stress |
| keywords[1].score | 0.7323113083839417 |
| keywords[1].display_name | Oxidative stress |
| keywords[2].id | https://openalex.org/keywords/diabetic-cardiomyopathy |
| keywords[2].score | 0.6859761476516724 |
| keywords[2].display_name | Diabetic cardiomyopathy |
| keywords[3].id | https://openalex.org/keywords/vegf-receptors |
| keywords[3].score | 0.6659919023513794 |
| keywords[3].display_name | VEGF receptors |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.6258540153503418 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/cardiology |
| keywords[5].score | 0.5118405222892761 |
| keywords[5].display_name | Cardiology |
| keywords[6].id | https://openalex.org/keywords/medicine |
| keywords[6].score | 0.501868486404419 |
| keywords[6].display_name | Medicine |
| keywords[7].id | https://openalex.org/keywords/cardiomyopathy |
| keywords[7].score | 0.4827372431755066 |
| keywords[7].display_name | Cardiomyopathy |
| keywords[8].id | https://openalex.org/keywords/reduction |
| keywords[8].score | 0.4755506217479706 |
| keywords[8].display_name | Reduction (mathematics) |
| keywords[9].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[9].score | 0.4175075888633728 |
| keywords[9].display_name | Diabetes mellitus |
| keywords[10].id | https://openalex.org/keywords/endocrinology |
| keywords[10].score | 0.3672904670238495 |
| keywords[10].display_name | Endocrinology |
| keywords[11].id | https://openalex.org/keywords/heart-failure |
| keywords[11].score | 0.21506723761558533 |
| keywords[11].display_name | Heart failure |
| keywords[12].id | https://openalex.org/keywords/type-2-diabetes |
| keywords[12].score | 0.11424872279167175 |
| keywords[12].display_name | Type 2 diabetes |
| language | en |
| locations[0].id | doi:10.3390/biom15081104 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210236520 |
| locations[0].source.issn | 2218-273X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2218-273X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Biomolecules |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.mdpi.com/2218-273X/15/8/1104/pdf?version=1753861922 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Biomolecules |
| locations[0].landing_page_url | https://doi.org/10.3390/biom15081104 |
| locations[1].id | pmid:40867548 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Biomolecules |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40867548 |
| locations[2].id | pmh:oai:doaj.org/article:273fc1a16b5c4ce9bb67a713f242a689 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Biomolecules, Vol 15, Iss 8, p 1104 (2025) |
| locations[2].landing_page_url | https://doaj.org/article/273fc1a16b5c4ce9bb67a713f242a689 |
| locations[3].id | pmh:oai:europepmc.org:11192199 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12383837 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5014756323 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-6538-9710 |
| authorships[0].author.display_name | Qamraa H. Alqahtani |
| authorships[0].countries | SA |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia |
| authorships[0].institutions[0].id | https://openalex.org/I28022161 |
| authorships[0].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[0].institutions[0].country_code | SA |
| authorships[0].institutions[0].display_name | King Saud University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Qamraa H. Alqahtani |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia |
| authorships[1].author.id | https://openalex.org/A5073428819 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Tahani Almatrafi |
| authorships[1].countries | SA |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Anatomy, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia |
| authorships[1].institutions[0].id | https://openalex.org/I28022161 |
| authorships[1].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[1].institutions[0].country_code | SA |
| authorships[1].institutions[0].display_name | King Saud University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Tahani A. ALMatrafi |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Anatomy, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia |
| authorships[2].author.id | https://openalex.org/A5042248280 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-3983-868X |
| authorships[2].author.display_name | Amira M. Badr |
| authorships[2].countries | SA |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia |
| authorships[2].institutions[0].id | https://openalex.org/I28022161 |
| authorships[2].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[2].institutions[0].country_code | SA |
| authorships[2].institutions[0].display_name | King Saud University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Amira M. Badr |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia |
| authorships[3].author.id | https://openalex.org/A5093455505 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Sumayya A. Alturaif |
| authorships[3].countries | SA |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia |
| authorships[3].institutions[0].id | https://openalex.org/I28022161 |
| authorships[3].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[3].institutions[0].country_code | SA |
| authorships[3].institutions[0].display_name | King Saud University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Sumayya A. Alturaif |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia |
| authorships[4].author.id | https://openalex.org/A5104185250 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Raeesa Mohammed |
| authorships[4].countries | SA |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Histology, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia |
| authorships[4].institutions[0].id | https://openalex.org/I28022161 |
| authorships[4].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[4].institutions[0].country_code | SA |
| authorships[4].institutions[0].display_name | King Saud University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Raeesa Mohammed |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Histology, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia |
| authorships[5].author.id | https://openalex.org/A5019471493 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Abdulaziz Siyal |
| authorships[5].countries | SA |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Histology, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia |
| authorships[5].institutions[0].id | https://openalex.org/I28022161 |
| authorships[5].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[5].institutions[0].country_code | SA |
| authorships[5].institutions[0].display_name | King Saud University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Abdulaziz Siyal |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Histology, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia |
| authorships[6].author.id | https://openalex.org/A5069316171 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-7311-1412 |
| authorships[6].author.display_name | Iman H. Hasan |
| authorships[6].countries | SA |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I28022161 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia |
| authorships[6].institutions[0].id | https://openalex.org/I28022161 |
| authorships[6].institutions[0].ror | https://ror.org/02f81g417 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I28022161 |
| authorships[6].institutions[0].country_code | SA |
| authorships[6].institutions[0].display_name | King Saud University |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Iman H. Hasan |
| authorships[6].is_corresponding | True |
| authorships[6].raw_affiliation_strings | Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.mdpi.com/2218-273X/15/8/1104/pdf?version=1753861922 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Sitagliptin Mitigates Diabetic Cardiomyopathy Through Oxidative Stress Reduction and Suppression of VEGF and FLT-1 Expression in Rats |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10401 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9997000098228455 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2712 |
| primary_topic.subfield.display_name | Endocrinology, Diabetes and Metabolism |
| primary_topic.display_name | Diabetes Treatment and Management |
| related_works | https://openalex.org/W2740693425, https://openalex.org/W2063464815, https://openalex.org/W2278512696, https://openalex.org/W2804643330, https://openalex.org/W2104058374, https://openalex.org/W2164375919, https://openalex.org/W2942365967, https://openalex.org/W2292250515, https://openalex.org/W2980745407, https://openalex.org/W2761661886 |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3390/biom15081104 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210236520 |
| best_oa_location.source.issn | 2218-273X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2218-273X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Biomolecules |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.mdpi.com/2218-273X/15/8/1104/pdf?version=1753861922 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Biomolecules |
| best_oa_location.landing_page_url | https://doi.org/10.3390/biom15081104 |
| primary_location.id | doi:10.3390/biom15081104 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210236520 |
| primary_location.source.issn | 2218-273X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2218-273X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Biomolecules |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.mdpi.com/2218-273X/15/8/1104/pdf?version=1753861922 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Biomolecules |
| primary_location.landing_page_url | https://doi.org/10.3390/biom15081104 |
| publication_date | 2025-07-30 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W1743014284, https://openalex.org/W2792805849, https://openalex.org/W3026907472, https://openalex.org/W6856628737, https://openalex.org/W3157906588, https://openalex.org/W4394743252, https://openalex.org/W2075957528, https://openalex.org/W4385063971, https://openalex.org/W4220913226, https://openalex.org/W3173303610, https://openalex.org/W2739819331, https://openalex.org/W2765451895, https://openalex.org/W3026721364, https://openalex.org/W4318054389, https://openalex.org/W2011446809, https://openalex.org/W2000601548, https://openalex.org/W2597773282, https://openalex.org/W3010288243, https://openalex.org/W6804156610, https://openalex.org/W4313544651, https://openalex.org/W3196992082, https://openalex.org/W4389893966, https://openalex.org/W2469752403, https://openalex.org/W2045308912, https://openalex.org/W2088866343, https://openalex.org/W3006949946, https://openalex.org/W2170003078, https://openalex.org/W2802176804, https://openalex.org/W2558136607, https://openalex.org/W2564408314, https://openalex.org/W3124098430, https://openalex.org/W3129996686, https://openalex.org/W2603126331, https://openalex.org/W2103813608, https://openalex.org/W2131295345, https://openalex.org/W4321598641, https://openalex.org/W4220930838, https://openalex.org/W2982430392, https://openalex.org/W6742771091, https://openalex.org/W1973431405, https://openalex.org/W1996446044, https://openalex.org/W2805986828, https://openalex.org/W2273394782, https://openalex.org/W2084432224, https://openalex.org/W1812298061, https://openalex.org/W4387530210, https://openalex.org/W2808704302, https://openalex.org/W4375932882, https://openalex.org/W2478430474, https://openalex.org/W4221028235, https://openalex.org/W2562974606, https://openalex.org/W2138787512, https://openalex.org/W2990297874, https://openalex.org/W3027123535, https://openalex.org/W2567630780, https://openalex.org/W3114503573, https://openalex.org/W2102874602, https://openalex.org/W4220931541, https://openalex.org/W3013986880, https://openalex.org/W3215005525, https://openalex.org/W4226310219, https://openalex.org/W4386998464, https://openalex.org/W2746249107 |
| referenced_works_count | 63 |
| abstract_inverted_index.A | 97 |
| abstract_inverted_index.I | 152 |
| abstract_inverted_index.a | 4, 45, 102, 162 |
| abstract_inverted_index.55 | 108 |
| abstract_inverted_index.In | 194 |
| abstract_inverted_index.an | 22 |
| abstract_inverted_index.as | 18, 44, 86, 88 |
| abstract_inverted_index.by | 9 |
| abstract_inverted_index.in | 15, 29, 66, 73, 138, 165, 216 |
| abstract_inverted_index.is | 3, 197 |
| abstract_inverted_index.of | 41, 99, 105, 207 |
| abstract_inverted_index.on | 71, 203 |
| abstract_inverted_index.to | 51, 58, 91, 111, 121, 199 |
| abstract_inverted_index.DM. | 35, 113 |
| abstract_inverted_index.Its | 141 |
| abstract_inverted_index.The | 68 |
| abstract_inverted_index.and | 62, 80, 94, 123, 148, 153, 168, 191 |
| abstract_inverted_index.but | 56 |
| abstract_inverted_index.can | 13 |
| abstract_inverted_index.for | 131 |
| abstract_inverted_index.has | 26 |
| abstract_inverted_index.its | 81, 89 |
| abstract_inverted_index.not | 49 |
| abstract_inverted_index.the | 39, 74, 204 |
| abstract_inverted_index.was | 115, 185 |
| abstract_inverted_index.(100 | 118 |
| abstract_inverted_index.(DM) | 2 |
| abstract_inverted_index.This | 36 |
| abstract_inverted_index.also | 57, 186 |
| abstract_inverted_index.dose | 104 |
| abstract_inverted_index.from | 158 |
| abstract_inverted_index.loss | 137 |
| abstract_inverted_index.only | 50 |
| abstract_inverted_index.oral | 23 |
| abstract_inverted_index.rats | 100, 160 |
| abstract_inverted_index.such | 17 |
| abstract_inverted_index.well | 87 |
| abstract_inverted_index.were | 129 |
| abstract_inverted_index.with | 34, 188 |
| abstract_inverted_index.(STZ) | 107 |
| abstract_inverted_index.CK-MB | 154 |
| abstract_inverted_index.FLT-1 | 169 |
| abstract_inverted_index.Heart | 156 |
| abstract_inverted_index.VEGF, | 167 |
| abstract_inverted_index.after | 126 |
| abstract_inverted_index.blood | 53, 145, 209 |
| abstract_inverted_index.days) | 120 |
| abstract_inverted_index.drug, | 25 |
| abstract_inverted_index.heart | 176 |
| abstract_inverted_index.mTOR, | 166 |
| abstract_inverted_index.mg/kg | 109 |
| abstract_inverted_index.offer | 200 |
| abstract_inverted_index.rats, | 125 |
| abstract_inverted_index.rats. | 140 |
| abstract_inverted_index.serum | 150 |
| abstract_inverted_index.study | 37 |
| abstract_inverted_index.sugar | 54 |
| abstract_inverted_index.which | 12, 127 |
| abstract_inverted_index.while | 172 |
| abstract_inverted_index.(VEGF) | 79 |
| abstract_inverted_index.(i.p.) | 110 |
| abstract_inverted_index.agent, | 47 |
| abstract_inverted_index.effect | 184 |
| abstract_inverted_index.factor | 78 |
| abstract_inverted_index.global | 5 |
| abstract_inverted_index.growth | 77 |
| abstract_inverted_index.health | 6, 61, 206 |
| abstract_inverted_index.immune | 170, 180 |
| abstract_inverted_index.impact | 40 |
| abstract_inverted_index.induce | 112 |
| abstract_inverted_index.levels | 55, 147 |
| abstract_inverted_index.marked | 8, 163 |
| abstract_inverted_index.normal | 122 |
| abstract_inverted_index.number | 98 |
| abstract_inverted_index.orally | 117 |
| abstract_inverted_index.result | 14 |
| abstract_inverted_index.showed | 161, 178 |
| abstract_inverted_index.single | 103 |
| abstract_inverted_index.stress | 215 |
| abstract_inverted_index.weight | 136 |
| abstract_inverted_index.(FLT-1) | 83 |
| abstract_inverted_index.cardiac | 64, 208 |
| abstract_inverted_index.chronic | 10 |
| abstract_inverted_index.control | 52 |
| abstract_inverted_index.effects | 202 |
| abstract_inverted_index.enhance | 59 |
| abstract_inverted_index.focused | 70 |
| abstract_inverted_index.glucose | 146 |
| abstract_inverted_index.levels. | 155 |
| abstract_inverted_index.rats’ | 175 |
| abstract_inverted_index.reduced | 144, 189 |
| abstract_inverted_index.samples | 128 |
| abstract_inverted_index.stress. | 96 |
| abstract_inverted_index.thereby | 211 |
| abstract_inverted_index.Diabetes | 0 |
| abstract_inverted_index.diabetic | 19, 124, 139, 159, 174, 217 |
| abstract_inverted_index.efficacy | 28 |
| abstract_inverted_index.explored | 38 |
| abstract_inverted_index.improved | 149 |
| abstract_inverted_index.increase | 164 |
| abstract_inverted_index.markers. | 193 |
| abstract_inverted_index.mellitus | 1 |
| abstract_inverted_index.mg/kg/90 | 119 |
| abstract_inverted_index.moderate | 179 |
| abstract_inverted_index.received | 101 |
| abstract_inverted_index.reducing | 213 |
| abstract_inverted_index.sections | 157, 177 |
| abstract_inverted_index.suppress | 92 |
| abstract_inverted_index.troponin | 151 |
| abstract_inverted_index.vascular | 60, 75, 205 |
| abstract_inverted_index.vessels, | 210 |
| abstract_inverted_index.apoptotic | 192 |
| abstract_inverted_index.challenge | 7 |
| abstract_inverted_index.collected | 130 |
| abstract_inverted_index.diabetes. | 67 |
| abstract_inverted_index.mitigated | 135 |
| abstract_inverted_index.oxidative | 95 |
| abstract_inverted_index.pathways, | 85 |
| abstract_inverted_index.patients. | 218 |
| abstract_inverted_index.potential | 43, 90 |
| abstract_inverted_index.reaction, | 171 |
| abstract_inverted_index.signaling | 84 |
| abstract_inverted_index.suggested | 198 |
| abstract_inverted_index.associated | 33, 187 |
| abstract_inverted_index.beneficial | 201 |
| abstract_inverted_index.myocardial | 214 |
| abstract_inverted_index.protective | 183 |
| abstract_inverted_index.reactions. | 181 |
| abstract_inverted_index.receptor-1 | 82 |
| abstract_inverted_index.resilience | 65 |
| abstract_inverted_index.strengthen | 63 |
| abstract_inverted_index.Sitagliptin | 114, 133, 196 |
| abstract_inverted_index.alleviating | 30 |
| abstract_inverted_index.alterations | 72 |
| abstract_inverted_index.conclusion, | 195 |
| abstract_inverted_index.endothelial | 76 |
| abstract_inverted_index.functioning | 48 |
| abstract_inverted_index.potentially | 212 |
| abstract_inverted_index.therapeutic | 46 |
| abstract_inverted_index.Sitagliptin, | 21 |
| abstract_inverted_index.administered | 116 |
| abstract_inverted_index.demonstrated | 27 |
| abstract_inverted_index.inflammation | 93 |
| abstract_inverted_index.complications | 16, 32 |
| abstract_inverted_index.inflammation, | 190 |
| abstract_inverted_index.investigation | 69 |
| abstract_inverted_index.significantly | 134, 143 |
| abstract_inverted_index.administration | 142 |
| abstract_inverted_index.cardiovascular | 31 |
| abstract_inverted_index.hyperglycemia, | 11 |
| abstract_inverted_index.investigation. | 132 |
| abstract_inverted_index.streptozotocin | 106 |
| abstract_inverted_index.Sitagliptin’s | 42, 182 |
| abstract_inverted_index.cardiomyopathy. | 20 |
| abstract_inverted_index.anti-hyperglycemic | 24 |
| abstract_inverted_index.sitagliptin-treated | 173 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5069316171 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 7 |
| corresponding_institution_ids | https://openalex.org/I28022161 |
| citation_normalized_percentile.value | 0.42309632 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |